Your browser doesn't support javascript.
loading
Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer.
Lin, Yingsong; Nakatochi, Masahiro; Hosono, Yasuyuki; Ito, Hidemi; Kamatani, Yoichiro; Inoko, Akihito; Sakamoto, Hiromi; Kinoshita, Fumie; Kobayashi, Yumiko; Ishii, Hiroshi; Ozaka, Masato; Sasaki, Takashi; Matsuyama, Masato; Sasahira, Naoki; Morimoto, Manabu; Kobayashi, Satoshi; Fukushima, Taito; Ueno, Makoto; Ohkawa, Shinichi; Egawa, Naoto; Kuruma, Sawako; Mori, Mitsuru; Nakao, Haruhisa; Adachi, Yasushi; Okuda, Masumi; Osaki, Takako; Kamiya, Shigeru; Wang, Chaochen; Hara, Kazuo; Shimizu, Yasuhiro; Miyamoto, Tatsuo; Hayashi, Yuko; Ebi, Hiromichi; Kohmoto, Tomohiro; Imoto, Issei; Kasugai, Yumiko; Murakami, Yoshinori; Akiyama, Masato; Ishigaki, Kazuyoshi; Matsuda, Koichi; Hirata, Makoto; Shimada, Kazuaki; Okusaka, Takuji; Kawaguchi, Takahisa; Takahashi, Meiko; Watanabe, Yoshiyuki; Kuriki, Kiyonori; Kadota, Aya; Okada, Rieko; Mikami, Haruo.
Afiliação
  • Lin Y; Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Aichi, 480-1195, Japan. linys@aichi-med-u.ac.jp.
  • Nakatochi M; Division of Public Health Informatics, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, 461-8673, Japan. mnakatochi@met.nagoya-u.ac.jp.
  • Hosono Y; Department of Nursing, Nagoya University Graduate School of Medicine, Nagoya, 461-8673, Japan. mnakatochi@met.nagoya-u.ac.jp.
  • Ito H; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Kamatani Y; Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Inoko A; Department of Descriptive Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
  • Sakamoto H; Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, 230-0045, Japan.
  • Kinoshita F; Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Kobayashi Y; Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Ishii H; Department of Pathology, Aichi Medical University School of Medicine, Nagakute, 480-1195, Japan.
  • Ozaka M; Genetics Division, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
  • Sasaki T; Data Science Division, Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, 461-8673, Japan.
  • Matsuyama M; Data Science Division, Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, 461-8673, Japan.
  • Sasahira N; Chiba Cancer Center, Chiba, 260-8717, Japan.
  • Morimoto M; Department of Hepato-biliary-pancreatic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Kobayashi S; Department of Hepato-biliary-pancreatic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Fukushima T; Department of Hepato-biliary-pancreatic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Ueno M; Department of Hepato-biliary-pancreatic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Ohkawa S; Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
  • Egawa N; Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
  • Kuruma S; Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
  • Mori M; Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
  • Nakao H; Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, 241-8515, Japan.
  • Adachi Y; Department of Gastroenterology, Tokyo Metropolitan Hiroo Hospital, Tokyo, 150-0013, Japan.
  • Okuda M; Department of Gastroenterology, Tokyo Metropolitan Komagome Hospital, Tokyo, 113-8677, Japan.
  • Osaki T; Hokkaido Chitose College of Rehabilitation, Hokkaido, 066-0055, Japan.
  • Kamiya S; Division of Hepatology and Pancreatology, Aichi Medical University School of Medicine, Nagakute, 480-1195, Japan.
  • Wang C; Sapporo Shirakabadai Hospital, Sapporo, 062-0052, Japan.
  • Hara K; Department of Pediatrics, Hyogo College of Medicine, Nishinomiya, Hyogo, 663-8501, Japan.
  • Shimizu Y; Department of Infectious Diseases, Kyorin University School of Medicine, Tokyo, 181-8611, Japan.
  • Miyamoto T; Department of Infectious Diseases, Kyorin University School of Medicine, Tokyo, 181-8611, Japan.
  • Hayashi Y; Department of Public Health, Aichi Medical University School of Medicine, Nagakute, Aichi, 480-1195, Japan.
  • Ebi H; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan.
  • Kohmoto T; Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan.
  • Imoto I; Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, 734-8553, Japan.
  • Kasugai Y; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Murakami Y; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Akiyama M; Department of Human Genetics, Tokushima University Graduate School of Medicine, Tokushima, 770-8503, Japan.
  • Ishigaki K; Division of Molecular Genetics, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Matsuda K; Division of Molecular Genetics, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Hirata M; Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, 464-8681, Japan.
  • Shimada K; Department of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
  • Okusaka T; Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Kawaguchi T; Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, 230-0045, Japan.
  • Takahashi M; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
  • Watanabe Y; Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, 230-0045, Japan.
  • Kuriki K; Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Kadota A; Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.
  • Okada R; Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Mikami H; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Nat Commun ; 11(1): 3175, 2020 06 24.
Article em En | MEDLINE | ID: mdl-32581250
Pancreatic cancer is the fourth leading cause of cancer-related deaths in Japan. To identify risk loci, we perform a meta-analysis of three genome-wide association studies comprising 2,039 pancreatic cancer patients and 32,592 controls in the Japanese population. Here, we identify 3 (13q12.2, 13q22.1, and 16p12.3) genome-wide significant loci (P < 5.0 × 10-8), of which 16p12.3 has not been reported in the Western population. The lead single nucleotide polymorphism (SNP) at 16p12.3 is rs78193826 (odds ratio = 1.46, 95% confidence interval = 1.29-1.66, P = 4.28 × 10-9), an Asian-specific, nonsynonymous glycoprotein 2 (GP2) gene variant. Associations between selected GP2 gene variants and pancreatic cancer are replicated in 10,822 additional cases and controls of East Asian origin. Functional analyses using cell lines provide supporting evidence of the effect of rs78193826 on KRAS activity. These findings suggest that GP2 gene variants are probably associated with pancreatic cancer susceptibility in populations of East Asian ancestry.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Predisposição Genética para Doença / Proteínas Ligadas por GPI Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Predisposição Genética para Doença / Proteínas Ligadas por GPI Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article